{{Rsnum
|rsid=16947
|Gene=CYP2D6
|Chromosome=22
|position=42523943
|Orientation=plus
|ReferenceAllele=T
|MissenseAllele=C
|GMAF=0.3425
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
The wild type (normal) allele at this SNP is (G). The (A) variant indicates the presence of a non-wild type CYP2D6 variant, but it appears in many different variants so it can not be used to determine the presence of any particular variant.

Inheriting a normal number of copies of this allele results in CYP2D6 function that is indistinguishable from wild-type (normal) activity. However, this variant has been seen present in higher copy numbers, and in these cases, can result in the ultrafast metabolizer phenotype {{PMID|7903454|OA=1
}}.
{{omim
|desc=DEBRISOQUINE, ULTRARAPID METABOLISM OF
|id=124030
|rsnum=16947
|variant=0007
}}
{{ neighbor
| rsid = 1065852
| distance = 2751
}}

{{PharmGKB
|RSID=rs16947
|Name_s=CYP2D6:2850C>T, part of CYP2D6*2A an extensive metabolizer haplotype.
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=PubMed ID:20309015
|Annotation=Risk or phenotype-associated allele: T. Phenotype: The CYP2D6*2A haplotype was associated with lower incidence of breast cancer on tamoxifen compared to placebo in a prevention study. The CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. Study size: 182. Study population/ethnicity: Women in the Italian Tamoxifen Prevention trial, Caucasian, Italy. Significance metric(s): p = 0.0001. Type of association: CO.
|Drugs=tamoxifen
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165349809
}}

{{PharmGKB
|RSID=rs16947
|Name_s=CYP2D6:2850C>T
|Gene_s=CYP2D6
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2d6/variant.jsp#ImportantVariantInformationforCYP2D6-888
|Annotation=This common SNP is found in the CYP2D6*2 haplotype among others.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145192
}}

{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=18698231
|Title=Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
|OA=1
}}

{{PMID Auto
|PMID=21071160
|Title=Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population.
}}

{{PMID Auto
|PMID=21840870
|Title=Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
}}

{{GET Evidence
|gene=CYP2D6
|aa_change=Cys296Arg
|aa_change_short=C296R
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs16947
|overall_frequency_n=6439
|overall_frequency_d=10742
|overall_frequency=0.599423
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=58
|n_articles=0
|n_articles_annotated=0
|nblosum100=8
|autoscore=0
|webscore=N
}}

{{PMID Auto
|PMID=22688145
|Title=Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters
}}

{{ClinVar
|ALT=G
|CAF=0.3425; 0.6575
|CHROM=22
|CLNALLE=1
|CLNHGVS=NC_000022.10:g.42523943A>G
|CLNSIG=1
|COMMON=1
|FwdALT=G
|FwdREF=A
|REF=A
|RSPOS=42523943
|Reversed=0
|SAO=0
|SSR=0
|Tags=PM;TPA;PMC;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;LSD;OM
|VC=SNV
|VP=0x05017800000117051e110100
|WGT=1
|dbSNPBuildID=60
|rsid=16947
}}

{{PMID Auto
|PMID=23130019
|Title=Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}